Article Figures & Data
Figures
- Figure 1 Change in Migraine-Specific Quality-of-Life Questionnaire (MSQ) scores from baseline over 3 months
Least-squares (LS) mean changes from baseline in (A) MSQ–role function-restrictive (MSQ-RFR), (B) MSQ–role function-preventive (MSQ-RFP), and (C) MSQ–emotional functioning (MSQ-EF) scores among participants with chronic migraine who were assigned to receive erenumab 70 mg, erenumab 140 mg, or placebo every month. The error bars represent 95% confidence intervals (CIs). Figure based on the efficacy analysis set. All p values ≤0.05, except for MSQ-RFP at month 2: erenumab 70 mg, p = 0.051, and erenumab 140 mg, p = 0.061. MID = minimally important difference.
- Figure 2 Change in Headache Impact Test–6 (HIT-6) total score from baseline over 3 months
Least-squares (LS) mean changes from baseline in HIT-6 scores among participants with chronic migraine who were assigned to receive erenumab 70 mg, erenumab 140 mg, or placebo every month. The error bars represent 95% confidence intervals (CIs). Figure based on the efficacy analysis set. All p values ≤0.05. MID = minimally important difference.
- Figure 3 Change in Migraine Disability Assessment (MIDAS) scores from baseline to month 3
Least-squares (LS) mean changes from baseline in (A) MIDAS total, (B) absenteeism, and (C) presenteeism scores among participants with chronic migraine who were assigned to receive erenumab 70 mg, erenumab 140 mg, or placebo every month. The error bars represent 95% confidence intervals (CIs). Figure based on the efficacy analysis set. All p values ≤0.05.
- Figure 4 Scatterplots of correlation between change in migraine days and change in patient-reported outcome scores
(A) Migraine-Specific Quality-of-Life Questionnaire–role function-restrictive (MSQ-RFR), (B) Migraine-Specific Quality-of-Life Questionnaire–role function-preventive (MSQ-RFP), (C) Migraine-Specific Quality-of-Life Questionnaire–emotional functioning (MSQ-EF), (D) Headache Impact Test–6 (HIT-6), and (E) Migraine Disability Assessment (MIDAS).
- Figure 5 Change in Patient-Reported Outcomes Measurement Information System (PROMIS) scores from baseline over 3 months
Least-squares (LS) mean changes from baseline in PROMIS scores among participants with chronic migraine who were assigned to receive erenumab 70 mg, erenumab 140 mg, or placebo every month. The error bars represent 95% confidence intervals (CIs). Figure based on the efficacy analysis set. All p values ≤0.01, except for erenumab 70 mg at month 1, p = 0.082.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
